Advanced search
Publication Cover
Cancer Management and Research Volume 14, 2022 - Issue
Submit an article Journal homepage
136
Views
4
CrossRef citations to date
0
Altmetric
REVIEW

RNA Modifications Meet Tumors

Zhiyuan Yang1 Department of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People’s Republic of China;2 Institute of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People’s Republic of ChinaView further author information
,
Siyu Zhang1 Department of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People’s Republic of China;2 Institute of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People’s Republic of ChinaView further author information
,
Tian Xia1 Department of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People’s Republic of China;2 Institute of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People’s Republic of ChinaView further author information
,
Yue Fan1 Department of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People’s Republic of China;2 Institute of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People’s Republic of ChinaView further author information
,
Ying Shan1 Department of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People’s Republic of China;2 Institute of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People’s Republic of ChinaView further author information
,
Kaiwen Zhang1 Department of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People’s Republic of China;2 Institute of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People’s Republic of ChinaView further author information
,
Jiayan Xiong1 Department of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People’s Republic of China;2 Institute of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People’s Republic of ChinaView further author information
,
Miao Gu1 Department of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People’s Republic of China;2 Institute of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People’s Republic of ChinaView further author information
&
Bo You1 Department of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People’s Republic of China;2 Institute of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People’s Republic of ChinaCorrespondence[email protected] [email protected]
View further author information
 show all
Pages 3223-3243 | Received 24 Sep 2022, Accepted 11 Nov 2022, Published online: 27 Nov 2023

References

  • Zhao LY, Song J, Liu Y., et al. Mapping the epigenetic modifications of DNA and RNA. Protein Cell. 2020;11(11):792–808. doi:10.1007/s13238-020-00733-7
  • Biswas S, Rao CM. Epigenetics in cancer: fundamentals and Beyond. Pharmacol Ther. 2017;173:118–134. doi:10.1016/j.pharmthera.2017.02.011
  • Boccaletto P, Stefaniak F, Ray A, et al. MODOMICS: a database of RNA modification pathways. 2021 update. Nucleic Acids Res. 2022;50(D1):D231–d235. doi:10.1093/nar/gkab1083
  • Schaefer MR. The Regulation of RNA Modification Systems: the Next Frontier in Epitranscriptomics? Genes. 2021;12(3):345. doi:10.3390/genes12030345
  • Xiong X, Li X, Yi C. N(1)-methyladenosine methylome in messenger RNA and non-coding RNA. Curr Opin Chem Biol. 2018;45:179–186. doi:10.1016/j.cbpa.2018.06.017
  • Cerneckis J, Cui Q, He C, et al. Decoding pseudouridine: an emerging target for therapeutic development. Trends Pharmacol Sci. 2022;43(6):522–535. doi:10.1016/j.tips.2022.03.008
  • Dominissini D, Moshitch-Moshkovitz S, Amariglio N, et al. Adenosine-to-inosine RNA editing meets cancer. Carcinogenesis. 2011;32(11):1569–1577. doi:10.1093/carcin/bgr124
  • Luo X, Li H, Liang J, et al. RMVar: an updated database of functional variants involved in RNA modifications. Nucleic Acids Res. 2021;49(D1):D1405–D1412. doi:10.1093/nar/gkaa811
  • Chen K, Song B, Tang Y, et al. RMDisease: a database of genetic variants that affect RNA modifications, with implications for epitranscriptome pathogenesis. Nucleic Acids Res. 2021;49(D1):D1396–D1404. doi:10.1093/nar/gkaa790
  • Vitale I, Manic G, Coussens LM, et al. Macrophages and Metabolism in the Tumor Microenvironment. Cell Metab. 2019;30(1):36–50. doi:10.1016/j.cmet.2019.06.001
  • Hinshaw DC, Shevde LA. The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019;79(18):4557–4566. doi:10.1158/0008-5472.CAN-18-3962
  • Hui L, Chen Y. Tumor microenvironment: sanctuary of the devil. Cancer Lett. 2015;368(1):7–13. doi:10.1016/j.canlet.2015.07.039
  • Denton AE, Roberts EW, Fearon DT. Stromal Cells in the Tumor Microenvironment. Adv Exp Med Biol. 2018;1060:99–114.
  • Wei CM, Gershowitz A, Moss B. Methylated nucleotides block 5’ terminus of HeLa cell messenger RNA. Cell. 1975;4(4):379–386. doi:10.1016/0092-8674(75)90158-0
  • Wei W, Ji X, Guo X, et al. Regulatory Role of N 6 -methyladenosine (m 6 A) Methylation in RNA Processing and Human Diseases. J Cell Biochem. 2017;118(9):2534–2543. doi:10.1002/jcb.25967
  • Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. 2019;20(10):608–624. doi:10.1038/s41580-019-0168-5
  • Oerum S, Meynier V, Catala M, Tisné C. A comprehensive review of m6A/m6Am RNA methyltransferase structures. Nucleic Acids Res. 2021;49(13):7239–7255. doi:10.1093/nar/gkab378
  • Tang Y, Chen K, Wu X, et al. DRUM: inference of Disease-Associated m(6)A RNA Methylation Sites From a Multi-Layer Heterogeneous Network. Front Genet. 2019;10:266. doi:10.3389/fgene.2019.00266
  • Song B, Huang D, Zhang Y, et al. m6A-TSHub: unveiling the Context-specific m(6)A Methylation and m6A-affecting Mutations in 23 Human Tissues. Genomics Proteomics Bioinformatics. 2022. doi:10.1016/j.gpb.2022.09.001
  • Wang S, Lv W, Li T, et al. Dynamic regulation and functions of mRNA m6A modification. Cancer Cell Int. 2022;22(1):48. doi:10.1186/s12935-022-02452-x
  • Meyer KD, Jaffrey SR. The dynamic epitranscriptome: N6-methyladenosine and gene expression control. Nat Rev Mol Cell Biol. 2014;15(5):313–326. doi:10.1038/nrm3785
  • Wang X, Lu Z, Gomez A, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505(7481):117–120. doi:10.1038/nature12730
  • Li ZX, Zheng Z-Q, Yang P-Y, et al. WTAP-mediated m(6)A modification of lncRNA DIAPH1-AS1 enhances its stability to facilitate nasopharyngeal carcinoma growth and metastasis. Cell Death Differ. 2022;29(6):1137–1151. doi:10.1038/s41418-021-00905-w
  • Yu D, Pan M, Li Y, et al. RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner. J Exp Clin Cancer Res. 2022;41(1):6. doi:10.1186/s13046-021-02212-1
  • Huang J, Sun W, Wang Z, et al. FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner. J Exp Clin Cancer Res. 2022;41(1):42. doi:10.1186/s13046-022-02254-z
  • Hu Y, Gong C, Li Z, et al. Demethylase ALKBH5 suppresses invasion of gastric cancer via PKMYT1 m6A modification. Mol Cancer. 2022;21(1):34. doi:10.1186/s12943-022-01522-y
  • Schöller E, Weichmann F, Treiber T, et al. Interactions, localization, and phosphorylation of the m 6 A generating METTL3–METTL14–WTAP complex. Rna. 2018;24(4):499–512. doi:10.1261/rna.064063.117
  • Fang R, Chen X, Zhang S, et al. EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. Nat Commun. 2021;12(1):177. doi:10.1038/s41467-020-20379-7
  • Li J, Xie H, Ying Y, et al. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer. Mol Cancer. 2020;19(1):152. doi:10.1186/s12943-020-01267-6
  • Dai X, Zhang T, Hua D. Ubiquitination and SUMOylation: protein homeostasis control over cancer. Epigenomics. 2022;14(1):43–58. doi:10.2217/epi-2021-0371
  • Shen D, Ding L, Lu Z, et al. METTL14-mediated Lnc-LSG1 m6A modification inhibits clear cell renal cell carcinoma metastasis via regulating ESRP2 ubiquitination. Mol Ther Nucleic Acids. 2022;27:547–561. doi:10.1016/j.omtn.2021.12.024
  • Zhu Y, Zhou B, Hu X, et al. LncRNA LINC00942 promotes chemoresistance in gastric cancer by suppressing MSI2 degradation to enhance c-Myc mRNA stability. Clin Transl Med. 2022;12(1):e703. doi:10.1002/ctm2.703
  • Wang Y, Chen Z. Long noncoding RNA UBA6-AS1 inhibits the malignancy of ovarian cancer cells via suppressing the decay of UBA6 mRNA. Bioengineered. 2022;13(1):178–189. doi:10.1080/21655979.2021.2011640
  • Yadav P, Subbarayalu P, Medina D, et al. M6A RNA Methylation Regulates Histone Ubiquitination to Support Cancer Growth and Progression. Cancer Res. 2022;82(10):1872–1889. doi:10.1158/0008-5472.CAN-21-2106
  • Han ZJ, Feng Y-H, Gu B-H, et al. The post-translational modification, SUMOylation, and cancer (Review). Int J Oncol. 2018;52(4):1081–1094. doi:10.3892/ijo.2018.4280
  • Du Y, Hou G, Zhang H, et al. SUMOylation of the m6A-RNA methyltransferase METTL3 modulates its function. Nucleic Acids Res. 2018;46(10):5195–5208. doi:10.1093/nar/gky156
  • Hou G, Zhao X, Li L, et al. SUMOylation of YTHDF2 promotes mRNA degradation and cancer progression by increasing its binding affinity with m6A-modified mRNAs. Nucleic Acids Res. 2021;49(5):2859–2877. doi:10.1093/nar/gkab065
  • Liu Q, Huang Q, Liu H, et al. SUMOylation of methyltransferase-like 3 facilitates colorectal cancer progression by promoting circ_0000677 in an m 6 A-dependent manner. J Gastroenterol Hepatol. 2022;37(4):700–713. doi:10.1111/jgh.15775
  • Liu J, Dou X, Chen C, et al. N 6 -methyladenosine of chromosome-associated regulatory RNA regulates chromatin state and transcription. Science. 2020;367(6477):580–586. doi:10.1126/science.aay6018
  • Wiener D, Schwartz S. The epitranscriptome beyond m(6)A. Nat Rev Genet. 2021;22(2):119–131. doi:10.1038/s41576-020-00295-8
  • Hussain S, Aleksic J, Blanco S, et al. Characterizing 5-methylcytosine in the mammalian epitranscriptome. Genome Biol. 2013;14(11):215. doi:10.1186/gb4143
  • Yang X, Yang Y, Sun B-F, et al. 5-methylcytosine promotes mRNA export - NSUN2 as the methyltransferase and ALYREF as an m(5)C reader. Cell Res. 2017;27(5):606–625. doi:10.1038/cr.2017.55
  • Zhang Q, Liu F, Chen W, et al. The role of RNA m 5 C modification in cancer metastasis. Int J Biol Sci. 2021;17(13):3369–3380. doi:10.7150/ijbs.61439
  • Chen YS, Yang W-L, Zhao Y-L, et al. Dynamic transcriptomic m 5 C and its regulatory role in RNA processing. Wiley Interdiscip Rev RNA. 2021;12(4):e1639. doi:10.1002/wrna.1639
  • Shinoda S, Kitagawa S, Nakagawa S, et al. Mammalian NSUN2 introduces 5-methylcytidines into mitochondrial tRNAs. Nucleic Acids Res. 2019;47(16):8734–8745. doi:10.1093/nar/gkz575
  • Pan J, Huang Z, Xu Y. m5C RNA Methylation Regulators Predict Prognosis and Regulate the Immune Microenvironment in Lung Squamous Cell Carcinoma. Front Oncol. 2021;11:657466. doi:10.3389/fonc.2021.657466
  • Pan J, Huang Z, Xu Y. m5C-Related lncRNAs Predict Overall Survival of Patients and Regulate the Tumor Immune Microenvironment in Lung Adenocarcinoma. Front Cell Dev Biol. 2021;9:671821. doi:10.3389/fcell.2021.671821
  • Huang Z, Li J, Chen J, et al. Construction of Prognostic Risk Model of 5-Methylcytosine-Related Long Non-Coding RNAs and Evaluation of the Characteristics of Tumor-Infiltrating Immune Cells in Breast Cancer. Front Genet. 2021;12:748279. doi:10.3389/fgene.2021.748279
  • Huang Z, Pan J, Wang H, et al. Prognostic Significance and Tumor Immune Microenvironment Heterogenicity of m5C RNA Methylation Regulators in Triple-Negative Breast Cancer. Front Cell Dev Biol. 2021;9:657547. doi:10.3389/fcell.2021.657547
  • Gao W, Chen L, Lin L, et al. SIAH1 reverses chemoresistance in epithelial ovarian cancer via ubiquitination of YBX-1. Oncogenesis. 2022;11(1):13. doi:10.1038/s41389-022-00387-6
  • Hu Y, Chen C, Tong X, et al. NSUN2 modified by SUMO-2/3 promotes gastric cancer progression and regulates mRNA m5C methylation. Cell Death Dis. 2021;12(9):842. doi:10.1038/s41419-021-04127-3
  • Delaunay S, Pascual G, Feng B, et al. Mitochondrial RNA modifications shape metabolic plasticity in metastasis. Nature. 2022;607(7919):593–603. doi:10.1038/s41586-022-04898-5
  • Delaunay S, Frye M. RNA modifications regulating cell fate in cancer. Nat Cell Biol. 2019;21(5):552–559. doi:10.1038/s41556-019-0319-0
  • Merrick WC, Pavitt GD. Protein Synthesis Initiation in Eukaryotic Cells. Cold Spring Harb Perspect Biol. 2018;10(12):a033092. doi:10.1101/cshperspect.a033092
  • Shatkin AJ. Capping of eucaryotic mRNAs. Cell. 1976;9(4 pt 2):645–653. doi:10.1016/0092-8674(76)90128-8
  • Orellana EA, Liu Q, Yankova E, et al. METTL1-mediated m(7)G modification of Arg-TCT tRNA drives oncogenic transformation. Mol Cell. 2021;81(16):3323–3338.e14. doi:10.1016/j.molcel.2021.06.031
  • Tomikawa C. 7-Methylguanosine Modifications in Transfer RNA (tRNA). Int J Mol Sci. 2018;19(12):4080. doi:10.3390/ijms19124080
  • Dai Z, Liu H, Liao J, et al. N(7)-Methylguanosine tRNA modification enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression. Mol Cell. 2021;81(16):3339–3355.e8. doi:10.1016/j.molcel.2021.07.003
  • Ma J, Han H, Huang Y, et al. METTL1/WDR4-mediated m(7)G tRNA modifications and m(7)G codon usage promote mRNA translation and lung cancer progression. Mol Ther. 2021;29(12):3422–3435. doi:10.1016/j.ymthe.2021.08.005
  • Ying X, Liu B, Yuan Z, et al. METTL1-m 7 G-EGFR/EFEMP1 axis promotes the bladder cancer development. Clin Transl Med. 2021;11(12):e675. doi:10.1002/ctm2.675
  • Katsara O, Schneider RJ. m(7)G tRNA modification reveals new secrets in the translational regulation of cancer development. Mol Cell. 2021;81(16):3243–3245. doi:10.1016/j.molcel.2021.07.030
  • Xia P, Zhang H, Xu K, et al. MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma. Cell Death Dis. 2021;12(7):691. doi:10.1038/s41419-021-03973-5
  • Pandolfini L, Barbieri I, Bannister AJ, et al. METTL1 Promotes let-7 MicroRNA Processing via m7G Methylation. Mol Cell. 2019;74(6):1278–1290.e9. doi:10.1016/j.molcel.2019.03.040
  • Jin H, Huo C, Zhou T, et al. m(1)A RNA Modification in Gene Expression Regulation. Genes. 2022;13(5):910. doi:10.3390/genes13050910
  • Xu L, Zhang C, Yin H, et al. RNA modifications act as regulators of cell death. RNA Biol. 2021;18(12):2183–2193. doi:10.1080/15476286.2021.1925460
  • Qu X, Zhang Y, Sang X, et al. Methyladenosine Modification in RNAs: from Regulatory Roles to Therapeutic Implications in Cancer. Cancers. 2022;14(13):3195. doi:10.3390/cancers14133195
  • Xu Y, Zhang M, Zhang Q, et al. Role of Main RNA Methylation in Hepatocellular Carcinoma: N6-Methyladenosine, 5-Methylcytosine, and N1-Methyladenosine. Front Cell Dev Biol. 2021;9:767668. doi:10.3389/fcell.2021.767668
  • Wang B, Niu L, Wang Z, et al. RNA m1A Methyltransferase TRMT6 Predicts Poorer Prognosis and Promotes Malignant Behavior in Glioma. Front Mol Biosci. 2021;8:692130. doi:10.3389/fmolb.2021.692130
  • Shao D, Li Y, Wu J, et al. An m6A/m5C/m1A/m7G-Related Long Non-coding RNA Signature to Predict Prognosis and Immune Features of Glioma. Front Genet. 2022;13:903117. doi:10.3389/fgene.2022.903117
  • Su Z, Monshaugen I, Wilson B, et al. TRMT6/61A-dependent base methylation of tRNA-derived fragments regulates gene-silencing activity and the unfolded protein response in bladder cancer. Nat Commun. 2022;13(1):2165. doi:10.1038/s41467-022-29790-8
  • Roy B. Effects of mRNA Modifications on Translation: an Overview. Methods Mol Biol. 2021;2298:327–356.
  • Martinez NM, Su A, Burns MC, et al. Pseudouridine synthases modify human pre-mRNA co-transcriptionally and affect pre-mRNA processing. Mol Cell. 2022;82(3):645–659.e9. doi:10.1016/j.molcel.2021.12.023
  • Cui Q, Yin K, Zhang X, et al. Targeting PUS7 suppresses tRNA pseudouridylation and glioblastoma tumorigenesis. Nat Cancer. 2021;2(9):932–949. doi:10.1038/s43018-021-00238-0
  • Song D, Guo M, Xu S, et al. HSP90-dependent PUS7 overexpression facilitates the metastasis of colorectal cancer cells by regulating LASP1 abundance. J Exp Clin Cancer Res. 2021;40(1):170. doi:10.1186/s13046-021-01951-5
  • Goncharov AO, Shender VO, Kuznetsova KG, et al. Interplay between A-to-I Editing and Splicing of RNA: a Potential Point of Application for Cancer Therapy. Int J Mol Sci. 2022;23(9):5240. doi:10.3390/ijms23095240
  • Song B, Shiromoto Y, Minakuchi M, et al. The role of RNA editing enzyme ADAR1 in human disease. Wiley Interdiscip Rev RNA. 2022;13(1):e1665. doi:10.1002/wrna.1665
  • Jiang L, Hao Y, Shao C, et al. ADAR1-mediated RNA editing links ganglioside catabolism to glioblastoma stem cell maintenance. J Clin Invest. 2022;132(6). doi:10.1172/JCI143397
  • Nakamura K, Shigeyasu K, Okamoto K, et al. ADAR1 and AZIN1 RNA editing function as an oncogene and contributes to immortalization in endometrial cancer. Gynecol Oncol. 2022;166(2):326–333. doi:10.1016/j.ygyno.2022.05.026
  • Baker AR, Miliotis C, Ramírez-Moya J, et al. Transcriptome Profiling of ADAR1 Targets in Triple-Negative Breast Cancer Cells Reveals Mechanisms for Regulating Growth and Invasion. Mol Cancer Res. 2022;20(6):960–971. doi:10.1158/1541-7786.MCR-21-0604
  • Eguchi Y, Itoh T, Tomizawa J. Antisense RNA. Annu Rev Biochem. 1991;60:631–652. doi:10.1146/annurev.bi.60.070191.003215
  • Kara G, Calin GA, Ozpolat B. RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev. 2022;182:114113. doi:10.1016/j.addr.2022.114113
  • Xu JZ, Zhang JL, Zhang WG. Antisense RNA: the new favorite in genetic research. J Zhejiang Univ Sci B. 2018;19(10):739–749. doi:10.1631/jzus.B1700594
  • Knowling S, Morris KV. Non-coding RNA and antisense RNA. Nature’s trash or treasure? Biochimie. 2011;93(11):1922–1927. doi:10.1016/j.biochi.2011.07.031
  • Golla U, Sesham K, Dallavalasa S, et al. ABHD11-AS1: an Emerging Long Non-Coding RNA (lncRNA) with Clinical Significance in Human Malignancies. Noncoding RNA. 2022;8(2). doi:10.3390/ncrna8020021
  • Tao L, Li D, Mu S, et al. LncRNA MAPKAPK5_AS1 facilitates cell proliferation in hepatitis B virus -related hepatocellular carcinoma. Lab Invest. 2022;102(5):494–504. doi:10.1038/s41374-022-00731-9
  • Hu Y, Tang J, Xu F, et al. A reciprocal feedback between N6-methyladenosine reader YTHDF3 and lncRNA DICER1-AS1 promotes glycolysis of pancreatic cancer through inhibiting maturation of miR-5586-5p. J Exp Clin Cancer Res. 2022;41(1):69. doi:10.1186/s13046-022-02285-6
  • Arneth B. Tumor Microenvironment. Medicina. 2019;56(1):15. doi:10.3390/medicina56010015
  • Jiang F, Hu Y, Liu X, et al. Methylation Pattern Mediated by m(6)A Regulator and Tumor Microenvironment Invasion in Lung Adenocarcinoma. Oxid Med Cell Longev. 2022;2022:2930310. doi:10.1155/2022/2930310
  • Liu T, Hu X, Lin C, et al. 5-methylcytosine RNA methylation regulators affect prognosis and tumor microenvironment in lung adenocarcinoma. Ann Transl Med. 2022;10(5):259. doi:10.21037/atm-22-500
  • Liu Y, Wang T, Fang Z, et al. Analysis of N6-methyladenosine-related lncRNAs in the tumor immune microenvironment and their prognostic role in pancreatic cancer. J Cancer Res Clin Oncol. 2022.
  • Wang R, Guo Y, Ma P, et al. Comprehensive Analysis of 5-Methylcytosine (m(5)C) Regulators and the Immune Microenvironment in Pancreatic Adenocarcinoma to Aid Immunotherapy. Front Oncol. 2022;12:851766. doi:10.3389/fonc.2022.851766
  • Zhang Y, Zhang K, Gong H, et al. Links Between N (6)-Methyladenosine and Tumor Microenvironments in Colorectal Cancer. Front Cell Dev Biol. 2022;10:807129. doi:10.3389/fcell.2022.807129
  • Fang X, Miao C, Zeng T, et al. Role of m 5 C RNA methylation regulators in colorectal cancer prognosis and immune microenvironment. J Clin Lab Anal. 2022;36(4):e24303. doi:10.1002/jcla.24303
  • Qing Y, Su R, Chen J. RNA modifications in hematopoietic malignancies: a new research frontier. Blood. 2021;138(8):637–648. doi:10.1182/blood.2019004263
  • Zhao Y, Peng H. The Role of N(6)-Methyladenosine (m(6)A) Methylation Modifications in Hematological Malignancies. Cancers. 2022;14(2):548.
  • Li J, Li Z, Bai X, et al. LncRNA UCA1 Promotes the Progression of AML by Upregulating the Expression of CXCR4 and CYP1B1 by Affecting the Stability of METTL14. J Oncol. 2022;2022:2756986. doi:10.1155/2022/2756986
  • Yang LR, Lin ZY, Hao QG, et al. The prognosis biomarkers based on m6A-related lncRNAs for myeloid leukemia patients. Cancer Cell Int. 2022;22(1):10. doi:10.1186/s12935-021-02428-3
  • Zheng G, Liu M, Chang X, et al. Comprehensive Analysis of N6-Methyladenosine-Related Long Noncoding RNA Prognosis of Acute Myeloid Leukemia and Immune Cell Infiltration. Front Genet. 2022;13:888173. doi:10.3389/fgene.2022.888173
  • Li Y, Zhao L, Li XF. Hypoxia and the Tumor Microenvironment. Technol Cancer Res Treat. 2021;20:15330338211036304. doi:10.1177/15330338211036304
  • Xu P, Hu K, Zhang P, et al. Hypoxia-mediated YTHDF2 overexpression promotes lung squamous cell carcinoma progression by activation of the mTOR/AKT axis. Cancer Cell Int. 2022;22(1):13. doi:10.1186/s12935-021-02368-y
  • An Y, Duan H. The role of m6A RNA methylation in cancer metabolism. Mol Cancer. 2022;21(1):14. doi:10.1186/s12943-022-01500-4
  • Ouyang W, Jiang Y, Bu S, et al. A Prognostic Risk Score Based on Hypoxia-, Immunity-, and Epithelial to-Mesenchymal Transition-Related Genes for the Prognosis and Immunotherapy Response of Lung Adenocarcinoma. Front Cell Dev Biol. 2021;9:758777. doi:10.3389/fcell.2021.758777
  • Wang JZ, Zhu W, Han J, et al. The role of the HIF-1α/ALYREF/PKM2 axis in glycolysis and tumorigenesis of bladder cancer. Cancer Commun. 2021;41(7):560–575. doi:10.1002/cac2.12158
  • Qing Y, Dong L, Gao L, et al. R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m(6)A/PFKP/LDHB axis. Mol Cell. 2021;81(5):922–939 e9. doi:10.1016/j.molcel.2020.12.026
  • Su R, Dong L, Li C, et al. R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m(6)A/MYC/CEBPA Signaling. Cell. 2018;172(1–2):90–105 e23. doi:10.1016/j.cell.2017.11.031
  • Lin R, Zhan M, Yang L, et al. Deoxycholic acid modulates the progression of gallbladder cancer through N(6)-methyladenosine-dependent microRNA maturation. Oncogene. 2020;39(26):4983–5000. doi:10.1038/s41388-020-1349-6
  • Szczerba BM, Castro-Giner F, Vetter M, et al. Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature. 2019;566(7745):553–557. doi:10.1038/s41586-019-0915-y
  • Yin H, Zhang X, Yang P, et al. RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming. Nat Commun. 2021;12(1):1394. doi:10.1038/s41467-021-21514-8
  • Li X. The m(6) A-BindingProtein YTHDF1 Mediates Immune Evasion. Cancer Discov. 2019;9(4):461. doi:10.1158/2159-8290.CD-RW2019-019
  • Han D, Liu J, Chen C, et al. Anti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cells. Nature. 2019;566(7743):270–274. doi:10.1038/s41586-019-0916-x
  • Song H, Song J, Cheng M, et al. METTL3-mediated m(6)A RNA methylation promotes the anti-tumour immunity of natural killer cells. Nat Commun. 2021;12(1):5522. doi:10.1038/s41467-021-25803-0
  • Dong F, Qin X, Wang B, et al. ALKBH5 Facilitates Hypoxia-Induced Paraspeckle Assembly and IL8 Secretion to Generate an Immunosuppressive Tumor Microenvironment. Cancer Res. 2021;81(23):5876–5888. doi:10.1158/0008-5472.CAN-21-1456
  • Qiu X, Yang S, Wang S, et al. M(6)A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma. Cancer Res. 2021;81(18):4778–4793. doi:10.1158/0008-5472.CAN-21-0468
  • Gao Z, Xu J, Zhang Z, et al. A Comprehensive Analysis of METTL1 to Immunity and Stemness in Pan-Cancer. Front Immunol. 2022;13:795240. doi:10.3389/fimmu.2022.795240
  • Liu T, Zhang J, Lin C, et al. Molecular Characterization Clinical and Immunotherapeutic Characteristics of m5C Regulator NOP2 Across 33 Cancer Types. Front Cell Dev Biol. 2022;10:839136. doi:10.3389/fcell.2022.839136
  • Zeng X, Liao G, Li S, et al. Eliminating METTL1-mediated accumulation of PMN-MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation. Hepatology. 2022.
  • Tong X, Xiang Y, Hu Y, et al. NSUN2 Promotes Tumor Progression and Regulates Immune Infiltration in Nasopharyngeal Carcinoma. Front Oncol. 2022;12:788801. doi:10.3389/fonc.2022.788801
  • van Niel G, Carter DRF, Clayton A, et al. Challenges and directions in studying cell-cell communication by extracellular vesicles. Nat Rev Mol Cell Biol. 2022;23(5):369–382. doi:10.1038/s41580-022-00460-3
  • Abu N, Rus Bakarurraini NAA. The interweaving relationship between extracellular vesicles and T cells in cancer. Cancer Lett. 2022;530:1–7. doi:10.1016/j.canlet.2021.12.007
  • Pastushenko I, Blanpain C. EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol. 2019;29(3):212–226. doi:10.1016/j.tcb.2018.12.001
  • Mittal V. Epithelial Mesenchymal Transition in Tumor Metastasis. Annu Rev Pathol. 2018;13:395–412. doi:10.1146/annurev-pathol-020117-043854
  • Zhao X, Li X, Li X. Multiple roles of m(6)A methylation in epithelial-mesenchymal transition. Mol Biol Rep. 2022.
  • Tao M, Li X, He L, et al. Decreased RNA m(6)A methylation enhances the process of the epithelial mesenchymal transition and vasculogenic mimicry in glioblastoma. Am J Cancer Res. 2022;12(2):893–906.
  • Zhu Y, Peng X, Zhou Q, et al. METTL3-mediated m6A modification of STEAP2 mRNA inhibits papillary thyroid cancer progress by blocking the Hedgehog signaling pathway and epithelial-to-mesenchymal transition. Cell Death Dis. 2022;13(4):358. doi:10.1038/s41419-022-04817-6
  • Yue B, Song C, Yang L, et al. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer. Mol Cancer. 2019;18(1):142. doi:10.1186/s12943-019-1065-4
  • Gu X, Zhou H, Chu Q, et al. Uncovering the Association Between m(5)C Regulator-Mediated Methylation Modification Patterns and Tumour Microenvironment Infiltration Characteristics in Hepatocellular Carcinoma. Front Cell Dev Biol. 2021;9:727935. doi:10.3389/fcell.2021.727935
  • Yuan H, Liu J, Zhao L, et al. Prognostic Risk Model and Tumor Immune Environment Modulation of m5C-Related LncRNAs in Pancreatic Ductal Adenocarcinoma. Front Immunol. 2021;12:800268. doi:10.3389/fimmu.2021.800268
  • Mabeta P, Hull R, Dlamini Z. LncRNAs and the Angiogenic Switch in Cancer: clinical Significance and Therapeutic Opportunities. Genes. 2022;13(1):152. doi:10.3390/genes13010152
  • Fu Z, Yuan Y. The role of tumor neogenesis pipelines in tumor progression and their therapeutic potential. Cancer Med. 2022. doi:10.1002/cam4.4979
  • Al-Ostoot FH, Salah S, Khamees HA, et al. Tumor angiogenesis: current challenges and therapeutic opportunities. Cancer Treat Res Commun. 2021;28:100422. doi:10.1016/j.ctarc.2021.100422
  • Guo YQ, Wang Q, Wang J-G, et al. METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression. Exp Hematol Oncol. 2022;11(1):14. doi:10.1186/s40164-022-00256-3
  • Zhao Y, Kong L, Pei Z, et al. m7G Methyltransferase METTL1 Promotes Post-ischemic Angiogenesis via Promoting VEGFA mRNA Translation. Front Cell Dev Biol. 2021;9:642080. doi:10.3389/fcell.2021.642080
  • Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299–309. doi:10.1038/s41586-019-1730-1
  • Casale J, Patel P. Fluorouracil. In: StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC; 2022.
  • Wigmore PM, Mustafa S, El-Beltagy M, et al. Effects of 5-FU. Adv Exp Med Biol. 2010;678:157–164.
  • Ma YN, Hong Y-G, Yu G-Y, et al. LncRNA LBX2-AS1 promotes colorectal cancer progression and 5-fluorouracil resistance. Cancer Cell Int. 2021;21(1):501. doi:10.1186/s12935-021-02209-y
  • Jiang Z, Hou Z, Liu W, et al. Circular RNA protein tyrosine kinase 2 (circPTK2) promotes colorectal cancer proliferation, migration invasion and chemoresistance. Bioengineered. 2022;13(1):810–823. doi:10.1080/21655979.2021.2012952
  • Moon B, Chang S. Exosome as a Delivery Vehicle for Cancer Therapy. Cells. 2022;11(3):316. doi:10.3390/cells11030316
  • Pan S, Deng Y, Fu J, et al. N6‑methyladenosine upregulates miR‑181d‑5p in exosomes derived from cancer‑associated fibroblasts to inhibit 5‑FU sensitivity by targeting NCALD in colorectal cancer. Int J Oncol. 2022;60(2). doi:10.3892/ijo.2022.5304
  • Taketo K, Konno M, Asai A, et al. The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Int J Oncol. 2018;52(2):621–629. doi:10.3892/ijo.2017.4219
  • Volk MS, Matz GJ. Cis-platinum. Otolaryngol Head Neck Surg. 1983;91(5):585–587. doi:10.1177/019459988309100524
  • Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378. doi:10.1016/j.ejphar.2014.07.025
  • Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–1883. doi:10.1038/onc.2011.384
  • Chen B, Jiang W, Huang Y, et al. N(7)-methylguanosine tRNA modification promotes tumorigenesis and chemoresistance through WNT/β-catenin pathway in nasopharyngeal carcinoma. Oncogene. 2022;41(15):2239–2253. doi:10.1038/s41388-022-02250-9
  • Liu Y, Yang C, Zhao Y, et al. Overexpressed methyltransferase-like 1 (METTL1) increased chemosensitivity of colon cancer cells to cisplatin by regulating miR-149-3p/S100A4/p53 axis. Aging. 2019;11(24):12328–12344. doi:10.18632/aging.102575
  • Zhou H, Meng M, Wang Z, et al. The Role of m5C-Related lncRNAs in Predicting Overall Prognosis and Regulating the Lower Grade Glioma Microenvironment. Front Oncol. 2022;12:814742. doi:10.3389/fonc.2022.814742
  • Nie S, Zhang L, Liu J, et al. ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer. J Exp Clin Cancer Res. 2021;40(1):284. doi:10.1186/s13046-021-02088-1
  • Yu H, Yang X, Tang J, et al. ALKBH5 Inhibited Cell Proliferation and Sensitized Bladder Cancer Cells to Cisplatin by m6A-CK2α-Mediated Glycolysis. Mol Ther Nucleic Acids. 2021;23:27–41. doi:10.1016/j.omtn.2020.10.031
  • Duan JL, Chen W, Xie -J-J, et al. A novel peptide encoded by N6-methyladenosine modified circMAP3K4 prevents apoptosis in hepatocellular carcinoma. Mol Cancer. 2022;21(1):93. doi:10.1186/s12943-022-01537-5
  • Sun Y, Dong D, Xia Y, et al. YTHDF1 promotes breast cancer cell growth, DNA damage repair and chemoresistance. Cell Death Dis. 2022;13(3):230. doi:10.1038/s41419-022-04672-5
  • Jarosz-Biej M, Smolarczyk R, Cichoń T, et al. Tumor Microenvironment as A “Game Changer” in Cancer Radiotherapy. Int J Mol Sci. 2019;20(13):3212. doi:10.3390/ijms20133212
  • Visvanathan A, Patil V, Arora A, et al. Essential role of METTL3-mediated m(6)A modification in glioma stem-like cells maintenance and radioresistance. Oncogene. 2018;37(4):522–533. doi:10.1038/onc.2017.351
  • Xu Z, Peng B, Cai Y, et al. N6-methyladenosine RNA modification in cancer therapeutic resistance: current status and perspectives. Biochem Pharmacol. 2020;182:114258. doi:10.1016/j.bcp.2020.114258
  • Mohd Idris RA, Mussa A, Ahmad S, et al. The Effects of Tamoxifen on Tolerogenic Cells in Cancer. Biology. 2022;11(8):1225. doi:10.3390/biology11081225
  • Liu X, Yuan J, Zhang X, et al. ATF3 Modulates the Resistance of Breast Cancer Cells to Tamoxifen through an N 6 -Methyladenosine-Based Epitranscriptomic Mechanism. Chem Res Toxicol. 2021;34(7):1814–1821. doi:10.1021/acs.chemrestox.1c00206
  • Liu X, Gonzalez G, Dai X, et al. Adenylate Kinase 4 Modulates the Resistance of Breast Cancer Cells to Tamoxifen through an m(6) A-BasedEpitranscriptomic Mechanism. Mol Ther. 2020;28(12):2593–2604. doi:10.1016/j.ymthe.2020.09.007
  • Wang W, Shao F, Yang X, et al. METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N(6)-methyladenosine-dependent YTHDF binding. Nat Commun. 2021;12(1):3803. doi:10.1038/s41467-021-23501-5
  • Fan HN, Chen Z-Y, Chen X-Y, et al. METTL14-mediated m(6)A modification of circORC5 suppresses gastric cancer progression by regulating miR-30c-2-3p/AKT1S1 axis. Mol Cancer. 2022;21(1):51. doi:10.1186/s12943-022-01521-z
  • Deng LJ, Deng W-Q, Fan S-R, et al. m6A modification: recent advances, anticancer targeted drug discovery and beyond. Mol Cancer. 2022;21(1):52. doi:10.1186/s12943-022-01510-2
  • Abdelgalil AA, Alkahtani HM, Al-Jenoobi FI. Sorafenib. Profiles Drug Subst Excip Relat Methodol. 2019;44:239–266.
  • Xia S, Pan Y, Liang Y, et al. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine. 2020;51:102610. doi:10.1016/j.ebiom.2019.102610
  • Kong H, Sun J, Zhang W, et al. Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3. Bioengineered. 2022;13(2):3108–3121. doi:10.1080/21655979.2022.2025701
  • Xu J, Wan Z, Tang M, et al. N(6)-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling. Mol Cancer. 2020;19(1):163. doi:10.1186/s12943-020-01281-8
  • Xiang Y, Guo Z, Zhu P, et al. Traditional Chinese medicine as a cancer treatment: modern perspectives of ancient but advanced science. Cancer Med. 2019;8(5):1958–1975. doi:10.1002/cam4.2108
  • Zhang X, Qiu H, Li C, et al. The positive role of traditional Chinese medicine as an adjunctive therapy for cancer. Biosci Trends. 2021;15(5):283–298. doi:10.5582/bst.2021.01318
  • Wu Y, Chen X, Bao W, et al. Effect of Humantenine on mRNA m6A Modification and Expression in Human Colon Cancer Cell Line HCT116. Genes. 2022;13(5):781. doi:10.3390/genes13050781
  • Jiang H, Yao Q, An Y, et al. Baicalin suppresses the progression of Type 2 diabetes-induced liver tumor through regulating METTL3/m(6)A/HKDC1 axis and downstream p-JAK2/STAT1/clevaged Capase3 pathway. Phytomedicine. 2022;94:153823. doi:10.1016/j.phymed.2021.153823
  • Wang H, Wei W, Zhang Z-Y, et al. TCF4 and HuR mediated-METTL14 suppresses dissemination of colorectal cancer via N6-methyladenosine-dependent silencing of ARRDC4. Cell Death Dis. 2022;13(1):3. doi:10.1038/s41419-021-04459-0
  • Luo M, Huang Z, Yang X, et al. PHLDB2 Mediates Cetuximab Resistance via Interacting With EGFR in Latent Metastasis of Colorectal Cancer. Cell Mol Gastroenterol Hepatol. 2022;13(4):1223–1242. doi:10.1016/j.jcmgh.2021.12.011
  • Guimarães-Teixeira C, Lobo J, Miranda‐Gonçalves V, et al. Downregulation of m 6 A writer complex member METTL14 in bladder urothelial carcinoma suppresses tumor aggressiveness. Mol Oncol. 2022;16:1841–1856. doi:10.1002/1878-0261.13181
  • Zhao C, Ling X, Xia Y, et al. LncRNA UCA1 promotes SOX12 expression in breast cancer by regulating m(6)A modification of miR-375 by METTL14 through DNA methylation. Cancer Gene Ther. 2022;29:1043–1055. doi:10.1038/s41417-021-00390-w
  • Xie Q, Li Z, Luo X, et al. piRNA-14633 promotes cervical cancer cell malignancy in a METTL14-dependent m6A RNA methylation manner. J Transl Med. 2022;20(1):51. doi:10.1186/s12967-022-03257-2
  • Wei YS, Yao DS, Li L, et al. METTL14在卵巢上皮性癌组织中的表达及对A2780、SKOV3细胞增殖、侵袭和迁移的影响 [Expression of METTL14 in epithelial ovarian cancer and the effect on cell proliferation, invasion and migration of A2780 and SKOV3 cells]. Zhonghua Fu Chan Ke Za Zhi. 2022;57(1):46–56. Chinese. doi:10.3760/cma.j.cn112141-20210925-00553
  • Geng Y, Guan R, Hong W, et al. Identification of m6A-related genes and m6A RNA methylation regulators in pancreatic cancer and their association with survival. Ann Transl Med. 2020;8(6):387. doi:10.21037/atm.2020.03.98
  • Yankova E, Blackaby W, Albertella M, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021;593(7860):597–601. doi:10.1038/s41586-021-03536-w
  • Sang L, Wu X, Yan T, et al. The m 6 A RNA methyltransferase METTL3/METTL14 promotes leukemogenesis through the mdm2/p53 pathway in acute myeloid leukemia. J Cancer. 2022;13(3):1019–1030. doi:10.7150/jca.60381
  • Liu X, Du Y, Huang Z, et al. Insights into roles of METTL14 in tumors. Cell Prolif. 2022;55(1):e13168. doi:10.1111/cpr.13168
  • Guan Q, Lin H, Miao L, et al. Functions, mechanisms, and therapeutic implications of METTL14 in human cancer. J Hematol Oncol. 2022;15(1):13. doi:10.1186/s13045-022-01231-5
  • Su R, Dong L, Li Y, et al. Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell. 2020;38(1):79–96.e11. doi:10.1016/j.ccell.2020.04.017
  • Zheng S, Han H, Lin S. N(6)-methyladenosine (m(6)A) RNA modification in tumor immunity. Cancer Biol Med. 2022. doi:10.20892/j.issn.2095-3941.2021.0534
  • Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411(6835):342–348. doi:10.1038/35077213
  • Morales-Valencia J, David G. The origins of cancer cell dormancy. Curr Opin Genet Dev. 2022;74:101914. doi:10.1016/j.gde.2022.101914
  • Peng J, Ma Y, Zhao X, et al. Constitutive β-Catenin Overexpression Represses Lncrna MIR100HG Transcription via HDAC6-Mediated Histone Modification in Colorectal Cancer. Mol Cancer Res. 2022;20(6):949–959. doi:10.1158/1541-7786.MCR-21-0923
  • Chen J, Zhuang Y, Wang P, et al. Reducing N6AMT1-mediated 6mA DNA modification promotes breast tumor progression via transcriptional repressing cell cycle inhibitors. Cell Death Dis. 2022;13(3):216. doi:10.1038/s41419-022-04661-8
  • Phillips EON, Gunjan A. Histone variants: the unsung guardians of the genome. DNA Repair. 2022;112:103301. doi:10.1016/j.dnarep.2022.103301
  • Sheng Y, Wei J, Yu F, et al. A critical role of nuclear m6A reader YTHDC1 in leukemogenesis by regulating MCM complex-mediated DNA replication. Blood. 2021;138(26):2838–2852. doi:10.1182/blood.2021011707
  • Kan RL, Chen J, Sallam T. Crosstalk between epitranscriptomic and epigenetic mechanisms in gene regulation. Trends Genet. 2022;38(2):182–193. doi:10.1016/j.tig.2021.06.014
  • Ohshiro T, Asai A, Konno M, et al. Direct observation of DNA alterations induced by a DNA disruptor. Sci Rep. 2022;12(1):6945. doi:10.1038/s41598-022-10725-8
  • Liu X, Rong F, Tang J, et al. Repression of p53 function by SIRT5-mediated desuccinylation at Lysine 120 in response to DNA damage. Cell Death Differ. 2022;29(4):722–736. doi:10.1038/s41418-021-00886-w
  • Wen J, Wang D. Deciphering the PTM codes of the tumor suppressor p53. J Mol Cell Biol. 2022;13(11):774–785. doi:10.1093/jmcb/mjab047
  • Wang YH, Ho TLF, Hariharan A, et al. Rapid recruitment of p53 to DNA damage sites directs DNA repair choice and integrity. Proc Natl Acad Sci U S A. 2022;119(10):e2113233119. doi:10.1073/pnas.2113233119
  • Zheng H, Zhu M, Li W, et al. m 5 C and m 6 A modification of long noncoding NKILA accelerates cholangiocarcinoma progression via the miR-582-3p-YAP1 axis. Liver Int. 2022;42:1144–1157. doi:10.1111/liv.15240
  • Song W, Ren J, Xiang R, et al. Cross-Talk Between m(6)A- and m(5) C-RelatedlncRNAs to Construct a Novel Signature and Predict the Immune Landscape of Colorectal Cancer Patients. Front Immunol. 2022;13:740960. doi:10.3389/fimmu.2022.740960
  • Wu S, Makeudom A, Sun X, et al. Overexpression of methyltransferase-like 3 and 14 in oral squamous cell carcinoma. J Oral Pathol Med. 2022;51(2):134–145. doi:10.1111/jop.13256

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.